2269:HKG
WuXi Biologics (Cayman) Inc
HK$ 48.20
arrow_downward
-0.90%(-0.44) 1D
10-р сарын 16, 16:08:14 (GMT+8) · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2269...
Open
HK$ 49.98
High
HK$ 50.85
Low
HK$ 45.82
Mkt. cap
198.43Т
Avg. vol.
30.42 сая
Volume
55.18 сая
P/E ratio
34.48
52-wk high
HK$ 58.00
52-wk low
HK$ 28.48
EPS
HK$ 1.40
Shares outstanding
1.23 тэрбум
No. of employees
15 мян
Open
HK$ 49.98
High
HK$ 50.85
Low
HK$ 45.82
Mkt. cap
198.43Т
Avg. vol.
30.42 сая
Volume
55.18 сая
P/E ratio
34.48
52-wk high
HK$ 58.00
52-wk low
HK$ 28.48
EPS
HK$ 1.40
Shares outstanding
1.23 тэрбум
No. of employees
15 мян
News stories
From web sources and news partners
The Frederick News-Post
·
1 цагийн өмнө
US markets are weighed down by an extended sell-off in the tech sector
TradingKey
·
45 минутын өмнө
US Stock Bull Market Enters Fifth Year: Can S&P 500 Withstand Rising Treasury Yield Pressures After Doubling?
MarketWatch
·
7 цагийн өмнө
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About WuXi Biologics (Cayman) Inc